Menu Search
Equities

Ono Pharmaceutical Co Ltd

4528N:MEX

Ono Pharmaceutical Co Ltd

Actions
  • Price (MXN)341.69
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Oct 17 2023 12:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Ono Pharmaceutical Co Ltd grew revenues 12.41% from 447.19bn to 502.67bn while net income improved 13.53% from 112.72bn to 127.98bn.
Gross margin75.38%
Net profit margin19.65%
Operating margin24.53%
Return on assets9.80%
Return on equity12.20%
Return on investment11.16%
More ▼

Cash flow in JPYView more

In 2024, Ono Pharmaceutical Co Ltd increased its cash reserves by 72.82%, or 70.01bn. The company earned 110.66bn from its operations for a Cash Flow Margin of 22.01%. In addition the company generated 48.08bn cash from investing, though they paid out 89.85bn more in financing than they received.
Cash flow per share239.86
Price/Cash flow per share7.69
Book value per share1,665.85
Tangible book value per share884.90
More ▼

Balance sheet in JPYView more

Ono Pharmaceutical Co Ltd appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 166.14bn.
Current ratio3.22
Quick ratio2.80
Total debt/total equity0.2066
Total debt/total capital0.1702
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.20%
Div growth rate (5 year)12.20%
Payout ratio (TTM)39.50%
EPS growth(5 years)21.61
EPS (TTM) vs
TTM 1 year ago		-21.52
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.